

References

1. Shulman, S.T., H.C. Friedmann, and R.H. Sims, *Theodor Escherich: the first pediatric infectious diseases physician?* Clin Infect Dis, 2007. **45**(8): p. 1025-9.
2. Blount, Z.D., *The unexhausted potential of E. coli.* eLife, 2015. **4**.
3. Tenailon, O., et al., *The population genetics of commensal Escherichia coli.* Nat Rev Microbiol, 2010. **8**(3): p. 207-17.
4. Sender, R., S. Fuchs, and R. Milo, *Revised estimates for the number of human and bacteria cells in the body.* PLoS Biol, 2016. **14**(8): p. e1002533.
5. Stecher, B. and W.D. Hardt, *The role of microbiota in infectious disease.* Trends Microbiol, 2008. **16**(3): p. 107-14.
6. Berg, R.D., *The indigenous gastrointestinal microflora.* Trends Microbiol, 1996. **4**(11): p. 430-5.
7. Hudault, S., J. Guignot, and A.L. Servin, *Escherichia coli strains colonising the gastrointestinal tract protect germfree mice against Salmonella typhimurium infection.* Gut, 2001. **49**(1): p. 47-55.
8. Bergholz, P.W., J.D. Noar, and D.H. Buckley, *Environmental patterns are imposed on the population structure of Escherichia coli after fecal deposition.* Appl Environ Microbiol, 2011. **77**(1): p. 211-9.
9. Goto, D.K. and T. Yan, *Genotypic diversity of Escherichia coli in the water and soil of tropical watersheds in Hawaii.* Appl Environ Microbiol, 2011. **77**(12): p. 3988-97.
10. Leimbach, A., J. Hacker, and U. Dobrindt, *E. coli as an all-rounder: the thin line between commensalism and pathogenicity.* Curr Top Microbiol Immunol, 2013. **358**: p. 3-32.
11. Nowrouzian, F., et al., *Escherichia coli in infants' intestinal microflora: colonization rate, strain turnover, and virulence gene carriage.* Pediatr Res, 2003. **54**(1): p. 8-14.
12. Caugant, D.A., B.R. Levin, and R.K. Selander, *Genetic diversity and temporal variation in the E. coli population of a human host.* Genetics, 1981. **98**(3): p. 467-90.
13. Selander, R.K. and B.R. Levin, *Genetic diversity and structure in Escherichia coli populations.* Science, 1980. **210**(4469): p. 545-7.
14. Escobar-Paramo, P., et al., *Large-scale population structure of human commensal Escherichia coli isolates.* Appl Environ Microbiol, 2004. **70**(9): p. 5698-700.
15. Skurnik, D., et al., *Characteristics of human intestinal Escherichia coli with changing environments.* Environ Microbiol, 2008. **10**(8): p. 2132-7.
16. Massot, M., et al., *Phylogenetic, virulence and antibiotic resistance characteristics of commensal strain populations of Escherichia coli from community subjects in the Paris area in 2010 and evolution over 30 years.* Microbiology, 2016. **162**(4): p. 642-50.
17. Smati, M., et al., *Quantitative analysis of commensal Escherichia coli populations reveals host-specific enterotypes at the intra-species level.* MicrobiologyOpen, 2015. **4**(4): p. 604-15.

18. Touchon, M., et al., *Organised genome dynamics in the Escherichia coli species results in highly diverse adaptive paths*. PLoS Genet, 2009. **5**(1): p. e1000344.
19. Lukjancenko, O., T.M. Wassenaar, and D.W. Ussery, *Comparison of 61 sequenced Escherichia coli genomes*. Microbiol Ecol, 2010. **60**(4): p. 708-20.
20. Kaas, R.S., et al., *Estimating variation within the genes and inferring the phylogeny of 186 sequenced diverse Escherichia coli genomes*. BMC Genomics, 2012. **13**: p. 577.
21. McInerney, J.O., A. McNally, and M.J. O'Connell, *Why prokaryotes have pangenomes*. Nat Microbiol, 2017. **2**: p. 17040.
22. Land, M., et al., *Insights from 20 years of bacterial genome sequencing*. Funct Integr Genomics, 2015. **15**(2): p. 141-61.
23. Cook, H. and D.W. Ussery, *Sigma factors in a thousand E. coli genomes*. Environ Microbiol, 2013. **15**(12): p. 3121-9.
24. Russo, T., *Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem*. Microbes and Infection, 2003. **5**(5): p. 449-456.
25. Scharff, R.L., *Economic burden from health losses due to foodborne illness in the United States*. J Food Prot, 2012. **75**(1): p. 123-31.
26. Kotloff, K.L., et al., *Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study*. Lancet, 2013. **382**(9888): p. 209-22.
27. Lanata, C.F., et al., *Global causes of diarrheal disease mortality in children <5 years of age: a systematic review*. PLoS One, 2013. **8**(9): p. e72788.
28. Flores-Mireles, A.L., et al., *Urinary tract infections: epidemiology, mechanisms of infection and treatment options*. Nat Rev Microbiol, 2015. **13**(5): p. 269-84.
29. Kaper, J.B., J.P. Nataro, and H.L. Mobley, *Pathogenic Escherichia coli*. Nat Rev Microbiol, 2004. **2**(2): p. 123-40.
30. Croxen, M.A. and B.B. Finlay, *Molecular mechanisms of Escherichia coli pathogenicity*. Nat Rev Microbiol, 2010. **8**(1): p. 26-38.
31. Martin, G.S., et al., *The epidemiology of sepsis in the United States from 1979 through 2000*. N Engl J Med, 2003. **348**(16): p. 1546-54.
32. Cohen, J., *The immunopathogenesis of sepsis*. Nature, 2002. **420**(6917): p. 885-91.
33. Kalra, O.P. and A. Raizada, *Approach to a patient with urosepsis*. J Glob Infect Dis, 2009. **1**(1): p. 57-63.
34. Marchetti, G., C. Tincati, and G. Silvestri, *Microbial translocation in the pathogenesis of HIV infection and AIDS*. Clin Microbiol Rev, 2013. **26**(1): p. 2-18.
35. Wiest, R., M. Lawson, and M. Geuking, *Pathological bacterial translocation in liver cirrhosis*. J Hepatol, 2014. **60**(1): p. 197-209.

36. Samet, A., et al., *Leukemia and risk of recurrent Escherichia coli bacteremia: genotyping implicates E. coli translocation from the colon to the bloodstream*. Eur J Clin Microbiol Infect Dis, 2013. **32**(11): p. 1393-400.
37. Green, S.I., et al., *Murine model of chemotherapy-induced extraintestinal pathogenic Escherichia coli translocation*. Infect Immun, 2015. **83**(8): p. 3243-56.
38. Laupland, K.B., et al., *Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region*. Clin Microbiol Infect, 2008. **14**(11): p. 1041-7.
39. Bou-Antoun, S., et al., *Descriptive epidemiology of Escherichia coli bacteraemia in England, April 2012 to March 2014*. Euro Surveill, 2016. **21**(35).
40. Jackson, L.A., et al., *Burden of community-onset Escherichia coli bacteremia in seniors*. J Infect Dis, 2005. **191**(9): p. 1523-9.
41. van der Mee-Marquet, N.L., et al., *Marked increase in incidence for bloodstream infections due to Escherichia coli, a side effect of previous antibiotic therapy in the elderly*. Front Microbiol, 2015. **6**: p. 646.
42. Schlackow, I., et al., *Increasing incidence of Escherichia coli bacteraemia is driven by an increase in antibiotic-resistant isolates: electronic database study in Oxfordshire 1999-2011*. J Antimicrob Chemother, 2012. **67**(6): p. 1514-24.
43. Reddy, E.A., A.V. Shaw, and J.A. Crump, *Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis*. Lancet Infect Dis, 2010. **10**(6): p. 417-32.
44. Deen, J., et al., *Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review*. Lancet Infect Dis, 2012. **12**(6): p. 480-487.
45. Southeast Asia Infectious Disease Clinical Research Network, *Causes and outcomes of sepsis in southeast Asia: a multinational multicentre cross-sectional study*. Lancet Glob Health, 2017. **5**(2): p. e157-e167.
46. Huson, M.A., et al., *Community-acquired bacterial bloodstream infections in HIV-infected patients: a systematic review*. Clin Infect Dis, 2014. **58**(1): p. 79-92.
47. Vlieghe, E.R., et al., *Bloodstream infection among adults in Phnom Penh, Cambodia: key pathogens and resistance patterns*. PLoS One, 2013. **8**(3): p. e59775.
48. Nga, T.V., et al., *The decline of typhoid and the rise of non-typhoid salmonellae and fungal infections in a changing HIV landscape: bloodstream infection trends over 15 years in southern Vietnam*. Trans R Soc Trop Med Hyg, 2012. **106**(1): p. 26-34.
49. Dat, V.Q., et al., *Bacterial bloodstream infections in a tertiary infectious diseases hospital in Northern Vietnam: aetiology, drug resistance, and treatment outcome*. BMC Infect Dis, 2017. **17**(1): p. 493.
50. Dale, A.P. and N. Woodford, *Extra-intestinal pathogenic Escherichia coli (ExPEC): Disease, carriage and clones*. J Infect, 2015. **71**(6): p. 615-26.

51. Martin, G.S., *Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes*. Expert Rev Anti Infect Ther, 2012. **10**(6): p. 701-6.
52. Lukac, P.J., R.A. Bonomo, and L.K. Logan, *Extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat*. Clin Infect Dis, 2015. **60**(9): p. 1389-97.
53. Nhu, N.T., et al., *Emergence of carbapenem-resistant Acinetobacter baumannii as the major cause of ventilator-associated pneumonia in intensive care unit patients at an infectious disease hospital in southern Vietnam*. J Med Microbiol, 2014. **63**: p. 1386-94.
54. Davies, J. and D. Davies, *Origins and evolution of antibiotic resistance*. Microbiol Mol Biol Rev, 2010. **74**(3): p. 417-33.
55. Aminov, R.I., *A brief history of the antibiotic era: lessons learned and challenges for the future*. Front Microbiol, 2010. **1**: p. 134.
56. Blair, J.M., et al., *Molecular mechanisms of antibiotic resistance*. Nat Rev Microbiol, 2015. **13**(1): p. 42-51.
57. Gao, R., et al., *Dissemination and mechanism for the MCR-1 colistin resistance*. PLoS Pathog, 2016. **12**(11): p. e1005957.
58. Liu, Y.Y., et al., *Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study*. Lancet Infect Dis, 2016. **16**(2): p. 161-8.
59. Tumbarello, M., et al., *Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy*. Antimicrob Agents Chemother, 2008. **52**(9): p. 3244-52.
60. Rodriguez-Bano, J., et al., *Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli*. J Clin Microbiol, 2010. **48**(5): p. 1726-31.
61. Thaden, J.T., et al., *Increased costs associated with bloodstream infections caused by multidrug-resistant Gram-negative bacteria are due primarily to patients with hospital-acquired infections*. Antimicrob Agents Chemother, 2017. **61**(3).
62. Lim, C., et al., *Epidemiology and burden of multidrug-resistant bacterial infection in a developing country*. eLife, 2016. **5**.
63. Hsu, L.Y., et al., *Carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia*. Clin Microbiol Rev, 2017. **30**(1): p. 1-22.
64. WHO, *Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics*. <http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en>, 2017.
65. Leibovici, L., et al., *The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection*. J Intern Med, 1998. **244**(5): p. 379-86.

66. Timsit, J.F., et al., *Treatment of bloodstream infections in ICUs*. BMC Infect Dis, 2014. **14**: p. 489.
67. Bevan, E.R., A.M. Jones, and P.M. Hawkey, *Global epidemiology of CTX-M beta-lactamases: temporal and geographical shifts in genotype*. J Antimicrob Chemother, 2017. **72**(8): p. 2145-2155.
68. Zhao, W.H. and Z.Q. Hu, *Epidemiology and genetics of CTX-M extended-spectrum beta-lactamases in Gram-negative bacteria*. Crit Rev Microbiol, 2013. **39**(1): p. 79-101.
69. Nordmann, P., et al., *The emerging NDM carbapenemases*. Trends Microbiol, 2011. **19**(12): p. 588-95.
70. Carattoli, A., et al., *Identification of plasmids by PCR-based replicon typing*. J Microbiol Methods, 2005. **63**(3): p. 219-28.
71. Thomas, C.M. and K.M. Nielsen, *Mechanisms of, and barriers to, horizontal gene transfer between bacteria*. Nat Rev Microbiol, 2005. **3**(9): p. 711-21.
72. Brauner, A., et al., *Characterization of Escherichia coli isolated in blood, urine and faeces from bacteraemic patients and possible spread of infection*. APMIS, 1991. **99**(4): p. 381-6.
73. Bergeron, C.R., et al., *Chicken as reservoir for extraintestinal pathogenic Escherichia coli in humans, Canada*. Emerg Infect Dis, 2012. **18**(3): p. 415-21.
74. Vincent, C., et al., *Food reservoir for Escherichia coli causing urinary tract infections*. Emerg Infect Dis, 2010. **16**(1): p. 88-95.
75. de Been, M., et al., *Dissemination of cephalosporin resistance genes between Escherichia coli strains from farm animals and humans by specific plasmid lineages*. PLoS Genet, 2014. **10**(12): p. e1004776.
76. Borjesson, S., et al., *Limited dissemination of extended-spectrum beta-lactamase- and plasmid-encoded AmpC-producing Escherichia coli from food and farm animals, Sweden*. Emerg Infect Dis, 2016. **22**(4): p. 634-40.
77. Lazarus, B., et al., *Do human extraintestinal Escherichia coli infections resistant to expanded-spectrum cephalosporins originate from food-producing animals? A systematic review*. Clin Infect Dis, 2015. **60**(3): p. 439-52.
78. Luna, G.M., et al., *Extraintestinal Escherichia coli carrying virulence genes in coastal marine sediments*. Appl Environ Microbiol, 2010. **76**(17): p. 5659-68.
79. Chung The, H., et al., *A high-resolution genomic analysis of multidrug-resistant hospital outbreaks of Klebsiella pneumoniae*. EMBO Mol Med, 2015. **7**(3): p. 227-39.
80. Page, A.J., et al., *Robust high-throughput prokaryote de novo assembly and improvement pipeline for Illumina data*. Microb Genom, 2016. **2**(8): p. e000083.
81. Gladman, S. and T. Seemann, *Velvet Optimiser* <https://github.com/tseemann/VelvetOptimiser>. 2008.

82. Zerbino, D.R. and E. Birney, *Velvet: algorithms for de novo short read assembly using de Bruijn graphs*. Genome Res, 2008. **18**(5): p. 821-9.
83. Boetzer, M., et al., *Scaffolding pre-assembled contigs using SSPACE*. Bioinformatics, 2011. **27**(4): p. 578-9.
84. Boetzer, M. and W. Pirovano, *Toward almost closed genomes with GapFiller*. Genome Biol, 2012. **13**(6): p. R56.
85. Seemann, T., *Prokka: rapid prokaryotic genome annotation*. Bioinformatics, 2014. **30**(14): p. 2068-9.
86. Pruitt, K.D., et al., *NCBI Reference Sequences (RefSeq): current status, new features and genome annotation policy*. Nucleic Acids Res, 2012. **40**(Database issue): p. D130-5.
87. Andrews, S., *FastQC* <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>. 2010.
88. Ewels, P., et al., *MultiQC: summarize analysis results for multiple tools and samples in a single report*. Bioinformatics, 2016. **32**(19): p. 3047-8.
89. Wood, D.E. and S.L. Salzberg, *Kraken: ultrafast metagenomic sequence classification using exact alignments*. Genome Biol, 2014. **15**(3): p. R46.
90. Parks, D.H., et al., *CheckM: assessing the quality of microbial genomes recovered from isolates, single cells, and metagenomes*. Genome Res, 2015. **25**(7): p. 1043-55.
91. Page, A.J., et al., *Comparison of multi-locus sequence typing software for next generation sequencing data*. bioRxiv, 2017.
92. Ochman, H. and R.K. Selander, *Standard reference strains of Escherichia coli from natural populations*. J Bacteriol, 1984. **157**(2): p. 690-3.
93. van Elsas, J.D., et al., *Survival of Escherichia coli in the environment: fundamental and public health aspects*. ISME J, 2011. **5**(2): p. 173-83.
94. Clermont, O., S. Bonacorsi, and E. Bingen, *Rapid and simple determination of the Escherichia coli phylogenetic group*. Appl Environ Microbiol, 2000. **66**(10): p. 4555-8.
95. Page, A.J., et al., *Roary: rapid large-scale prokaryote pan genome analysis*. Bioinformatics, 2015. **31**(22): p. 3691-3.
96. Price, M.N., P.S. Dehal, and A.P. Arkin, *FastTree: computing large minimum evolution trees with profiles instead of a distance matrix*. Mol Biol Evol, 2009. **26**(7): p. 1641-50.
97. Cheng, L., et al., *Hierarchical and spatially explicit clustering of DNA sequences with BAPS software*. Mol Biol Evol, 2013. **30**(5): p. 1224-8.
98. Letunic, I. and P. Bork, *Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees*. Nucleic Acids Res, 2016. **44**(W1): p. W242-5.
99. Hadfield, J., et al., *Phandango: an interactive viewer for bacterial population genomics*. bioRxiv, 2017.
100. Rasko, D.A., et al., *The pangenome structure of Escherichia coli: comparative genomic analysis of E. coli commensal and pathogenic isolates*. J Bacteriol, 2008. **190**(20): p. 6881-93.

101. Salipante, S.J., et al., *Large-scale genomic sequencing of extraintestinal pathogenic Escherichia coli strains*. Genome Res, 2015. **25**(1): p. 119-28.
102. Lau, S.H., et al., *Major uropathogenic Escherichia coli strain isolated in the northwest of England identified by multilocus sequence typing*. J Clin Microbiol, 2008. **46**(3): p. 1076-80.
103. Holt, K.E., et al., *Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health*. Proc Natl Acad Sci U S A, 2015. **112**(27): p. E3574-81.
104. Harris, S.R., et al., *Whole-genome sequencing for analysis of an outbreak of meticillin-resistant Staphylococcus aureus: a descriptive study*. Lancet Infect Dis, 2013. **13**(2): p. 130-136.
105. Adams-Sapper, S., et al., *Clonal composition and community clustering of drug-susceptible and -resistant Escherichia coli isolates from bloodstream infections*. Antimicrob Agents Chemother, 2013. **57**(1): p. 490-7.
106. Zhao, L., et al., *Molecular epidemiology and genetic diversity of fluoroquinolone-resistant Escherichia coli isolates from patients with community-onset infections in 30 Chinese county hospitals*. J Clin Microbiol, 2015. **53**(3): p. 766-70.
107. Boyd, E.F. and D.L. Hartl, *Chromosomal regions specific to pathogenic isolates of Escherichia coli have a phylogenetically clustered distribution*. J Bacteriol, 1998. **180**(5): p. 1159-65.
108. Kohler, C.D. and U. Dobrindt, *What defines extraintestinal pathogenic Escherichia coli?* Int J Med Microbiol, 2011. **301**(8): p. 642-7.
109. Starcic Erjavec, M. and D. Zgur-Bertok, *Virulence potential for extraintestinal infections among commensal Escherichia coli isolated from healthy humans - the Trojan horse within our gut*. FEMS Microbiol Lett, 2015. **362**(5).
110. Foxman, B., *Epidemiology of urinary tract infections: incidence, morbidity, and economic costs*. Am J Med, 2002. **113 Suppl 1A**: p. 5S-13S.
111. Wiles, T.J., R.R. Kulesus, and M.A. Mulvey, *Origins and virulence mechanisms of uropathogenic Escherichia coli*. Exp Mol Pathol, 2008. **85**(1): p. 11-9.
112. Luthje, P. and A. Brauner, *Virulence factors of uropathogenic E. coli and their interaction with the host*. Adv Microb Physiol, 2014. **65**: p. 337-72.
113. Snyder, J.A., et al., *Role of phase variation of type 1 fimbriae in a uropathogenic Escherichia coli cystitis isolate during urinary tract infection*. Infect Immun, 2006. **74**(2): p. 1387-93.
114. Holden, V.I. and M.A. Bachman, *Diverging roles of bacterial siderophores during infection*. Metallomics, 2015. **7**(6): p. 986-95.
115. Cross, A.S., et al., *The importance of the K1 capsule in invasive infections caused by Escherichia coli*. J Infect Dis, 1984. **149**(2): p. 184-93.
116. Allen, P.M., et al., *Contribution of capsular polysaccharide and surface properties to virulence of Escherichia coli K1*. Infect Immun, 1987. **55**(11): p. 2662-8.

117. Poirel, L., et al., *Genetic features of bla_{NDM-1}-positive Enterobacteriaceae*. Antimicrob Agents Chemother, 2011. **55**(11): p. 5403-7.
118. Livermore, D.M., *Current epidemiology and growing resistance of Gram-negative pathogens*. Korean J Intern Med, 2012. **27**(2): p. 128-42.
119. Carattoli, A., et al., *In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing*. Antimicrob Agents Chemother, 2014. **58**(7): p. 3895-903.
120. Lan, R., et al., *Molecular evolutionary relationships of enteroinvasive Escherichia coli and Shigella spp.* Infect Immun, 2004. **72**(9): p. 5080-8.
121. Croxen, M.A., et al., *Recent advances in understanding enteric pathogenic Escherichia coli*. Clin Microbiol Rev, 2013. **26**(4): p. 822-80.
122. Carattoli, A., *Resistance plasmid families in Enterobacteriaceae*. Antimicrob Agents Chemother, 2009. **53**(6): p. 2227-38.
123. Hunt, M., et al., *ARIBA: rapid antimicrobial resistance genotyping directly from sequencing reads*. bioRxiv, 2017.
124. Kleinheinz, K.A., K.G. Joensen, and M.V. Larsen, *Applying the ResFinder and VirulenceFinder web-services for easy identification of acquired antibiotic resistance and E. coli virulence genes in bacteriophage and prophage nucleotide sequences*. Bacteriophage, 2014. **4**(1): p. e27943.
125. Chen, L., et al., *VFDB 2016: hierarchical and refined dataset for big data analysis--10 years on*. Nucleic Acids Res, 2016. **44**(D1): p. D694-7.
126. Antipov, D., et al., *plasmidSPAdes: assembling plasmids from whole genome sequencing data*. Bioinformatics, 2016. **32**(22): p. 3380-3387.
127. Bankevich, A., et al., *SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing*. J Comput Biol, 2012. **19**(5): p. 455-77.
128. Wick, R.R., et al., *Bandage: interactive visualization of de novo genome assemblies*. Bioinformatics, 2015. **31**(20): p. 3350-2.
129. CLSI, *Standards for antimicrobial susceptibility testing; twenty-fourth informational supplement, CLSI document M100-S24*. Clinical and Laboratory Standards Institute, Wayne, PA, 2014.
130. Drieux, L., et al., *Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide*. Clin Microbiol Infect, 2008. **14 Suppl 1**: p. 90-103.
131. Wickham, H., *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New York. 2009.
132. Simms, A.N. and H.L. Mobley, *PapX, a P fimbrial operon-encoded inhibitor of motility in uropathogenic Escherichia coli*. Infect Immun, 2008. **76**(11): p. 4833-41.
133. Raymond, K.N., E.A. Dertz, and S.S. Kim, *Enterobactin: an archetype for microbial iron transport*. Proc Natl Acad Sci U S A, 2003. **100**(7): p. 3584-8.

134. Bugarel, M., et al., *Virulence gene profiling of enterohemorrhagic (EHEC) and enteropathogenic (EPEC) Escherichia coli strains: a basis for molecular risk assessment of typical and atypical EPEC strains*. BMC Microbiol, 2011. **11**: p. 142.
135. Petty, N.K., et al., *Global dissemination of a multidrug resistant Escherichia coli clone*. Proc Natl Acad Sci U S A, 2014. **111**(15): p. 5694-9.
136. Liu, Y.-Y., et al., *Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study*. Lancet Infect Dis, 2016. **16**(2): p. 161-168.
137. Tada, T., et al., *Emergence of colistin-resistant Escherichia coli clinical isolates harboring mcr-1 in Vietnam*. Int J Infect Dis, 2017.
138. Dona, V., et al., *Heterogeneous genetic location of mcr-1 in colistin-resistant Escherichia coli isolated from humans and retail chicken meat in Switzerland: Emergence of mcr-1-carrying IncK2 plasmids*. Antimicrob Agents Chemother, 2017.
139. Rutherford, K., et al., *Artemis: sequence visualization and annotation*. Bioinformatics, 2000. **16**(10): p. 944-5.
140. Josenhans, C. and S. Suerbaum, *The role of motility as a virulence factor in bacteria*. Int J Med Microbiol, 2002. **291**(8): p. 605-14.
141. Kao, C.Y., et al., *The complex interplay among bacterial motility and virulence factors in different Escherichia coli infections*. Eur J Clin Microbiol Infect Dis, 2014. **33**(12): p. 2157-62.
142. Fischbach, M.A., et al., *How pathogenic bacteria evade mammalian sabotage in the battle for iron*. Nat Chem Biol, 2006. **2**(3): p. 132-8.
143. Sakamoto, K., et al., *IL-22 controls iron-dependent nutritional immunity against systemic bacterial infections*. Sci Immunol, 2017. **2**(8).
144. Antao, E.M., L.H. Wieler, and C. Ewers, *Adhesive threads of extraintestinal pathogenic Escherichia coli*. Gut Pathog, 2009. **1**(1): p. 22.
145. Lasaro, M.A., et al., *FIC fimbriae play an important role in biofilm formation and intestinal colonization by the Escherichia coli commensal strain Nissle 1917*. Appl Environ Microbiol, 2009. **75**(1): p. 246-51.
146. Cirl, C., et al., *Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins*. Nat Med, 2008. **14**(4): p. 399-406.
147. Garcia, T.A., et al., *Cytotoxic necrotizing factor 1 and hemolysin from uropathogenic Escherichia coli elicit different host responses in the murine bladder*. Infect Immun, 2013. **81**(1): p. 99-109.
148. Sugumar, M., et al., *Detection of OXA-1 beta-lactamase gene of Klebsiella pneumoniae from blood stream infections (BSI) by conventional PCR and in-silico analysis to understand the mechanism of OXA mediated resistance*. PLoS One, 2014. **9**(3): p. e91800.

149. Brynildsrud, O., et al., *Rapid scoring of genes in microbial pan-genome-wide association studies with Scoary*. Genome Biol, 2016. **17**(1): p. 238.
150. Snitkin, E.S., et al., *Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing*. Sci Transl Med, 2012. **4**(148): p. 148ra116.
151. Koser, C.U., et al., *Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak*. N Engl J Med, 2012. **366**(24): p. 2267-75.
152. Stoesser, N., et al., *Genome sequencing of an extended series of NDM-producing Klebsiella pneumoniae isolates from neonatal infections in a Nepali hospital characterizes the extent of community- versus hospital-associated transmission in an endemic setting*. Antimicrob Agents Chemother, 2014. **58**(12): p. 7347-57.
153. Stoesser, N., et al., *Evolutionary history of the global emergence of the Escherichia coli epidemic clone ST131*. mBio, 2016. **7**(2): p. e02162.
154. Reiss, D.J. and H.L. Mobley, *Determination of target sequence bound by PapX, repressor of bacterial motility, in flhD promoter using systematic evolution of ligands by exponential enrichment (SELEX) and high throughput sequencing*. J Biol Chem, 2011. **286**(52): p. 44726-38.
155. Stoesser, N., et al., *Extensive within-host diversity in fecally carried extended-spectrum-beta-lactamase-producing Escherichia coli isolates: Implications for transmission analyses*. J Clin Microbiol, 2015. **53**(7): p. 2122-31.
156. Gorrie, C.L., et al., *Gastrointestinal carriage is a major reservoir of K. pneumoniae infection in intensive care patients*. Clin Infect Dis, 2017.
157. Martin, R.M., et al., *Molecular epidemiology of colonizing and infecting isolates of Klebsiella pneumoniae*. mSphere, 2016. **1**(5).
158. Stecher, B., et al., *Gut inflammation can boost horizontal gene transfer between pathogenic and commensal Enterobacteriaceae*. Proc Natl Acad Sci U S A, 2012. **109**(4): p. 1269-74.
159. Ben Zakour, N.L., et al., *Sequential acquisition of virulence and fluoroquinolone resistance has shaped the evolution of Escherichia coli ST131*. mBio, 2016. **7**(2): p. e00347-16.
160. Alhashash, F., et al., *Multidrug-resistant Escherichia coli bacteremia*. Emerg Infect Dis, 2013. **19**(10): p. 1699-701.
161. Kallonen, T., et al., *Systematic longitudinal survey of invasive Escherichia coli in England demonstrates a stable population structure only transiently disturbed by the emergence of ST131*. Genome Res, 2017.
162. Platell, J.L., et al., *Prominence of an O75 clonal group (clonal complex 14) among non-ST131 fluoroquinolone-resistant Escherichia coli causing extraintestinal infections in humans and dogs in Australia*. Antimicrob Agents Chemother, 2012. **56**(7): p. 3898-904.
163. Chang, J., et al., *Prevalence and characteristics of lactose non-fermenting Escherichia coli in urinary isolates*. J Infect Chemother, 2014. **20**(11): p. 738-40.

164. Xia, S., et al., *Dominance of CTX-M-type extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolated from patients with community-onset and hospital-onset infection in China*. PLoS One, 2014. **9**(7): p. e100707.
165. Xia, L., et al., *Prevalence of ST1193 clone and IncII/ST16 plasmid in E. coli isolates carrying blaCTX-M-55 gene from urinary tract infections patients in China*. Sci Rep, 2017. **7**: p. 44866.
166. Chen, S.L., et al., *Genomic diversity and fitness of E. coli strains recovered from the intestinal and urinary tracts of women with recurrent urinary tract infection*. Sci Transl Med, 2013. **5**(184): p. 184ra60.
167. Watts, R.E., et al., *Contribution of siderophore systems to growth and urinary tract colonization of asymptomatic bacteriuria Escherichia coli*. Infect Immun, 2012. **80**(1): p. 333-44.
168. Panigrahi, P., et al., *A randomized synbiotic trial to prevent sepsis among infants in rural India*. Nature, 2017. **548**(7668): p. 407-412.
169. Ferrieres, L., V. Hancock, and P. Klemm, *Biofilm exclusion of uropathogenic bacteria by selected asymptomatic bacteriuria Escherichia coli strains*. Microbiology, 2007. **153**(Pt 6): p. 1711-9.
170. Abraham, S.N. and Y. Miao, *The nature of immune responses to urinary tract infections*. Nat Rev Immunol, 2015. **15**(10): p. 655-63.
171. Spaulding, C.N., et al., *Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist*. Nature, 2017. **546**(7659): p. 528-532.
172. Roberts, J.A., et al., *Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein*. J Urol, 2004. **171**(4): p. 1682-5.
173. Brumbaugh, A.R. and H.L. Mobley, *Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine*. Expert Rev Vaccines, 2012. **11**(6): p. 663-76.